Becton, Dickinson and Company (NYSE:BDX) Holdings Decreased by Keybank National Association OH

Keybank National Association OH reduced its stake in shares of Becton, Dickinson and Company (NYSE:BDX) by 2.9% during the fourth quarter, Holdings Channel.com reports. The firm owned 15,511 shares of the medical instruments supplier’s stock after selling 459 shares during the period. Keybank National Association OH’s holdings in Becton, Dickinson and Company were worth $3,519,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors have also modified their holdings of the stock. State Street Corp raised its stake in shares of Becton, Dickinson and Company by 0.8% during the third quarter. State Street Corp now owns 13,953,116 shares of the medical instruments supplier’s stock valued at $3,364,096,000 after purchasing an additional 106,616 shares in the last quarter. Geode Capital Management LLC raised its stake in shares of Becton, Dickinson and Company by 1.8% during the third quarter. Geode Capital Management LLC now owns 6,285,513 shares of the medical instruments supplier’s stock valued at $1,510,050,000 after purchasing an additional 111,101 shares in the last quarter. Massachusetts Financial Services Co. MA raised its stake in shares of Becton, Dickinson and Company by 9.4% during the third quarter. Massachusetts Financial Services Co. MA now owns 5,365,554 shares of the medical instruments supplier’s stock valued at $1,293,635,000 after purchasing an additional 460,440 shares in the last quarter. Charles Schwab Investment Management Inc. raised its stake in shares of Becton, Dickinson and Company by 2.2% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 3,053,416 shares of the medical instruments supplier’s stock valued at $692,729,000 after purchasing an additional 66,873 shares in the last quarter. Finally, Nordea Investment Management AB raised its position in Becton, Dickinson and Company by 31.0% in the fourth quarter. Nordea Investment Management AB now owns 2,844,566 shares of the medical instruments supplier’s stock worth $647,082,000 after acquiring an additional 673,568 shares in the last quarter. 86.97% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In related news, Director Jeffrey William Henderson bought 1,500 shares of Becton, Dickinson and Company stock in a transaction that occurred on Monday, February 10th. The stock was purchased at an average cost of $233.62 per share, for a total transaction of $350,430.00. Following the acquisition, the director now owns 8,015 shares in the company, valued at $1,872,464.30. This trade represents a 23.02 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director Bertram L. Scott sold 700 shares of the business’s stock in a transaction that occurred on Wednesday, February 12th. The stock was sold at an average price of $227.99, for a total value of $159,593.00. Following the completion of the sale, the director now owns 36,033 shares of the company’s stock, valued at approximately $8,215,163.67. This trade represents a 1.91 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 10,544 shares of company stock worth $2,370,309. 0.36% of the stock is currently owned by insiders.

Analyst Ratings Changes

Several brokerages have commented on BDX. Barclays boosted their price target on shares of Becton, Dickinson and Company from $278.00 to $279.00 and gave the stock an “overweight” rating in a research report on Friday, February 14th. StockNews.com raised Becton, Dickinson and Company from a “hold” rating to a “buy” rating in a research note on Wednesday. Finally, Piper Sandler lifted their price target on Becton, Dickinson and Company from $275.00 to $280.00 and gave the stock an “overweight” rating in a research note on Tuesday, January 28th. Eight investment analysts have rated the stock with a buy rating, According to MarketBeat.com, Becton, Dickinson and Company currently has a consensus rating of “Buy” and an average target price of $278.29.

Becton, Dickinson and Company Stock Down 0.0 %

Shares of Becton, Dickinson and Company stock opened at $224.17 on Thursday. The firm has a market cap of $64.37 billion, a price-to-earnings ratio of 37.24, a P/E/G ratio of 1.63 and a beta of 0.40. The company has a debt-to-equity ratio of 0.69, a current ratio of 1.13 and a quick ratio of 0.63. Becton, Dickinson and Company has a 52-week low of $218.75 and a 52-week high of $251.99. The stock has a 50-day simple moving average of $233.02 and a 200-day simple moving average of $232.83.

Becton, Dickinson and Company (NYSE:BDX) last announced its quarterly earnings results on Wednesday, February 5th. The medical instruments supplier reported $3.43 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.00 by $0.43. Becton, Dickinson and Company had a return on equity of 15.74% and a net margin of 8.47%. On average, equities research analysts expect that Becton, Dickinson and Company will post 14.43 earnings per share for the current fiscal year.

Becton, Dickinson and Company declared that its Board of Directors has approved a share repurchase program on Tuesday, January 28th that allows the company to buyback 10,000,000 shares. This buyback authorization allows the medical instruments supplier to repurchase shares of its stock through open market purchases. Stock buyback programs are usually an indication that the company’s leadership believes its shares are undervalued.

Becton, Dickinson and Company Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Monday, March 31st. Stockholders of record on Monday, March 10th will be issued a dividend of $1.04 per share. The ex-dividend date of this dividend is Monday, March 10th. This represents a $4.16 annualized dividend and a dividend yield of 1.86%. Becton, Dickinson and Company’s dividend payout ratio is 69.10%.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.